Search
Avapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigational[A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal
Categories: MATE 2-K Inhibitors, MATE 1 InhibitorsPafolacianine
go.drugbank.com/drugs/DB15413ApprovedInvestigationalPafolacianine, or OTL38, is a folate analogue conjugated with a fluorescent dye that absorbs light in the near-infrared (NIR) spectrum [A242572] within a range of 760 nm to 785 nm, with a peak absorption … It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingBenzhydrocodone
go.drugbank.com/drugs/DB15465ApprovedBenzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.
Brensocatib
go.drugbank.com/drugs/DB15638Approved[A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation. … [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamideBerotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigationalBerotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). … [L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798]
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride, 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamideNavacaprant
go.drugbank.com/drugs/DB16068InvestigationalBTRX-335140 is under investigation in clinical trial NCT04221230 (Study in Major Depressive Disorder With BTRX-335140 vs Placebo).
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingFexuprazan
go.drugbank.com/drugs/DB16078InvestigationalAbeprazan is under investigation in clinical trial NCT04341454 (Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis).
Synonyms: 1H-PYRROLE-3-METHANAMINE, 5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-N-METHYL-, 5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-N-METHYL-1H-PYRROLE-3-METHANAMINECategories: Heterocyclic Compounds, 1-RingAtogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigational[A239094] The "gepants" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesProducts: AQUIPTA® 60 MG, AQUIPTA® 10 MG